Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALG-AML1/2016 AML induction and salvage chemotherapy comparison
2017-001308-31Phase 4Terminated
- Sponsor
- Polish Adult Leukemia Group
- Start
- Apr 2017
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cytarabine, daunorubicin, cladribine, fludarabine, idarubicin and 2 more in acute myeloid leukemia (AML) (4 arms), sponsored by Polish Adult Leukemia Group. Primary endpoints: Complete remission rate after induction and Complete remission rate after reinduction. Started Apr 2017; status: terminated.
02
Drugs
cytarabinedaunorubicincladribinefludarabineidarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2017-001308-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001308-31.